share_log

BTIG Initiates Coverage On MariMed With Buy Rating, Announces Price Target of $0.85

Benzinga Real-time News ·  Oct 28, 2022 09:18

BTIG analyst Jonathan Decourcey initiates coverage on MariMed (OTC:MRMD) with a Buy rating and announces Price Target of $0.85.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment